These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 19766755)

  • 1. Comparison of incidence of acute myocardial infarction in patients with type 2 diabetes mellitus following initiation of neutral protamine Hagedorn insulin versus insulin glargine.
    Rhoads GG; Kosiborod M; Nesto RW; Fonseca VA; Lu SE; Zhang Q; Foody JM
    Am J Cardiol; 2009 Oct; 104(7):910-6. PubMed ID: 19766755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes.
    Hassan K; Rodriguez LM; Johnson SE; Tadlock S; Heptulla RA
    Pediatrics; 2008 Mar; 121(3):e466-72. PubMed ID: 18299307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence rates of heart failure, stroke, and acute myocardial infarction among Type 2 diabetic patients using insulin glargine and other insulin.
    Juhaeri J; Gao S; Dai WS
    Pharmacoepidemiol Drug Saf; 2009 Jun; 18(6):497-503. PubMed ID: 19326365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: a retrospective database analysis.
    Lee LJ; Yu AP; Johnson SJ; Birnbaum HG; Atanasov P; Buesching DP; Jackson JA; Davidson JA
    Diabetes Res Clin Pract; 2010 Jan; 87(1):108-16. PubMed ID: 19896233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products.
    Bullano MF; Al-Zakwani IS; Fisher MD; Menditto L; Willey VJ
    Curr Med Res Opin; 2005 Feb; 21(2):291-8. PubMed ID: 15802000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study.
    Schöffski O; Breitscheidel L; Benter U; Dippel FW; Müller M; Volk M; Pfohl M
    J Med Econ; 2008; 11(4):695-712. PubMed ID: 19450076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization.
    Cooke CE; Lee HY; Tong YP; Haines ST
    Curr Med Res Opin; 2010 Jan; 26(1):231-8. PubMed ID: 19921965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy.
    Yokoyama H; Tada J; Kamikawa F; Kanno S; Yokota Y; Kuramitsu M
    Diabetes Res Clin Pract; 2006 Jul; 73(1):35-40. PubMed ID: 16513202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials.
    Bazzano LA; Lee LJ; Shi L; Reynolds K; Jackson JA; Fonseca V
    Diabet Med; 2008 Aug; 25(8):924-32. PubMed ID: 18959605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of glycaemic control in patients with Type 2 diabetes on basal insulin and fixed combination oral antidiabetic treatment: results of a pilot study.
    De Mattia G; Laurenti O; Moretti A
    Acta Diabetol; 2009 Mar; 46(1):67-73. PubMed ID: 19030772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes.
    Päivärinta M; Tapanainen P; Veijola R
    Pediatr Diabetes; 2008 Jun; 9(3 Pt 2):83-90. PubMed ID: 18221431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Injection of acidic or neutral insulin and pain: a single-center, prospective, controlled, noninterventional study in pediatric patients with type 1 diabetes mellitus.
    Karges B; Muche R; Riegger I; Moritz M; Heinze E; Debatin KM; Wabitsch M; Karges W
    Clin Ther; 2006 Dec; 28(12):2094-101. PubMed ID: 17296465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosing of insulin glargine in the treatment of type 2 diabetes.
    Barnett A
    Clin Ther; 2007 Jun; 29(6):987-99. PubMed ID: 17692716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the subcutaneous absorption of insulin glargine (Lantus) and NPH insulin in patients with Type 2 diabetes.
    Luzio SD; Beck P; Owens DR
    Horm Metab Res; 2003 Jul; 35(7):434-8. PubMed ID: 12931275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma glucose and hypoglycaemia following exercise in people with Type 1 diabetes: a comparison of three basal insulins.
    Arutchelvam V; Heise T; Dellweg S; Elbroend B; Minns I; Home PD
    Diabet Med; 2009 Oct; 26(10):1027-32. PubMed ID: 19900235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycaemic control in type 2 diabetes mellitus patients undergoing major surgery: comparison of three subcutaneous insulin regimens.
    Mathur SK; Bansal A; Khan ZY
    J Indian Med Assoc; 2009 Nov; 107(11):759-61. PubMed ID: 20469779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn therapy for newly diagnosed type 1 diabetes.
    Al Shamsi AM
    Pediatrics; 2008 Sep; 122(3):675-6; author reply 676. PubMed ID: 18762540
    [No Abstract]   [Full Text] [Related]  

  • 19. The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes.
    Baxter MA
    Acta Diabetol; 2008 Dec; 45(4):253-68. PubMed ID: 18766296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower severe hypoglycemia risk: insulin glargine versus NPH insulin in type 2 diabetes.
    Dailey G; Strange P
    Am J Manag Care; 2008 Jan; 14(1):25-30. PubMed ID: 18197742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.